Merck sold $29.5 billion of Keytruda in 2024. That is 45.9% of the company’s $64.2 billion in worldwide sales (analysis
Why “Diversified Pipeline” Doesn’t Mean Diversified Patent Risk Read Post »
Novartis reported Entresto net sales of $1,253 million in the fourth quarter of 2025. The same quarter in 2024 was
Your CDMO Contract Renews Before the Patent Expires. You Are Negotiating Blind. Read Post »
Forest Laboratories and Actavis projected that only 30 percent of Namenda IR users would move to Namenda XR voluntarily before
Evergreening Fails When a Judge Reads Your Own Marketing Materials Read Post »
On July 22, 2025, the Federal Circuit denied Novartis’s motion for an injunction pending appeal and lifted its own short-term
The Drug Patent Litigation Docket Is a Leading Indicator Your Model Doesn’t Use Read Post »
On January 10, 2025, the Federal Circuit reversed a ruling that had invalidated Novartis’s Entresto patent, U.S. Patent No. 8,101,659.
Patent Win vs. Settlement: What Five Drug Cases Show Investors Read Post »
The Short Answer: Why Does a ‘Strong Patent Portfolio’ Slide Worry Investors? A slide that says ‘Strong Patent Portfolio’ makes
A ‘Strong Patent Portfolio’ Slide Is a Red Flag: What the Evidence Shows Read Post »
Sign in or create a free account to read this DrugPatentWatch article
